iGB5Cer (d18:1/18:0) is a glycosphingolipid subtype that can be used as a useful standard in the research of the potential adjuvant development for cancer vaccines.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.